254 related articles for article (PubMed ID: 19446882)
1. A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome.
Ståhl AL; Kristoffersson A; Olin AI; Olsson ML; Roodhooft AM; Proesmans W; Karpman D
Mol Immunol; 2009 Jul; 46(11-12):2236-43. PubMed ID: 19446882
[TBL] [Abstract][Full Text] [Related]
2. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
[TBL] [Abstract][Full Text] [Related]
3. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.
Nilsson SC; Karpman D; Vaziri-Sani F; Kristoffersson AC; Salomon R; Provot F; Fremeaux-Bacchi V; Trouw LA; Blom AM
Mol Immunol; 2007 Mar; 44(8):1835-44. PubMed ID: 17084897
[TBL] [Abstract][Full Text] [Related]
4. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.
Arvidsson I; Ståhl AL; Hedström MM; Kristoffersson AC; Rylander C; Westman JS; Storry JR; Olsson ML; Karpman D
J Immunol; 2015 Mar; 194(5):2309-18. PubMed ID: 25637016
[TBL] [Abstract][Full Text] [Related]
5. The role of defective complement control in hemolytic uremic syndrome.
Zipfel PF; Misselwitz J; Licht C; Skerka C
Semin Thromb Hemost; 2006 Mar; 32(2):146-54. PubMed ID: 16575689
[TBL] [Abstract][Full Text] [Related]
6. Human platelet-initiated formation and uptake of the C5-9 complex of human complement.
Zimmerman TS; Kolb WP
J Clin Invest; 1976 Jan; 57(1):203-11. PubMed ID: 812888
[TBL] [Abstract][Full Text] [Related]
7. Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells.
Heinen S; Józsi M; Hartmann A; Noris M; Remuzzi G; Skerka C; Zipfel PF
J Am Soc Nephrol; 2007 Feb; 18(2):506-14. PubMed ID: 17229916
[TBL] [Abstract][Full Text] [Related]
8. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.
Kavanagh D; Kemp EJ; Mayland E; Winney RJ; Duffield JS; Warwick G; Richards A; Ward R; Goodship JA; Goodship TH
J Am Soc Nephrol; 2005 Jul; 16(7):2150-5. PubMed ID: 15917334
[TBL] [Abstract][Full Text] [Related]
9. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.
Fremeaux-Bacchi V; Moulton EA; Kavanagh D; Dragon-Durey MA; Blouin J; Caudy A; Arzouk N; Cleper R; Francois M; Guest G; Pourrat J; Seligman R; Fridman WH; Loirat C; Atkinson JP
J Am Soc Nephrol; 2006 Jul; 17(7):2017-25. PubMed ID: 16762990
[TBL] [Abstract][Full Text] [Related]
10. Unusual clinical severity of complement membrane cofactor protein-associated hemolytic-uremic syndrome and uniparental isodisomy.
Fremeaux-Bacchi V; Sanlaville D; Menouer S; Blouin J; Dragon-Durey MA; Fischbach M; Vekemans M; Fridman WH
Am J Kidney Dis; 2007 Feb; 49(2):323-9. PubMed ID: 17261436
[TBL] [Abstract][Full Text] [Related]
11. Complement dysfunction in hemolytic uremic syndrome.
Zipfel PF; Skerka C
Curr Opin Rheumatol; 2006 Sep; 18(5):548-55. PubMed ID: 16896298
[TBL] [Abstract][Full Text] [Related]
12. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.
Kavanagh D; Burgess R; Spitzer D; Richards A; Diaz-Torres ML; Goodship JA; Hourcade DE; Atkinson JP; Goodship TH
Mol Immunol; 2007 May; 44(12):3162-7. PubMed ID: 17368771
[TBL] [Abstract][Full Text] [Related]
13. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation.
Ståhl AL; Vaziri-Sani F; Heinen S; Kristoffersson AC; Gydell KH; Raafat R; Gutierrez A; Beringer O; Zipfel PF; Karpman D
Blood; 2008 Jun; 111(11):5307-15. PubMed ID: 18268093
[TBL] [Abstract][Full Text] [Related]
14. Inherited deficiency of membrane cofactor protein expression and varying manifestations of recurrent atypical hemolytic uremic syndrome in a sibling pair.
Couzi L; Contin-Bordes C; Marliot F; Sarrat A; Grimal P; Moreau JF; Merville P; Fremeaux-Bacchi V
Am J Kidney Dis; 2008 Aug; 52(2):e5-9. PubMed ID: 18514989
[TBL] [Abstract][Full Text] [Related]
15. Terminal complement complex (C5b-9) in children with recurrent hemolytic uremic syndrome.
Prüfer F; Scheiring J; Sautter S; Jensen DB; Treichl R; Würzner R; Zimmerhackl LB
Semin Thromb Hemost; 2006 Mar; 32(2):121-7. PubMed ID: 16575687
[TBL] [Abstract][Full Text] [Related]
16. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
Tschopp J; Chonn A; Hertig S; French LE
J Immunol; 1993 Aug; 151(4):2159-65. PubMed ID: 8345200
[TBL] [Abstract][Full Text] [Related]
17. Update on evaluating complement in hemolytic uremic syndrome.
Kavanagh D; Goodship TH
Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):565-71. PubMed ID: 18089972
[TBL] [Abstract][Full Text] [Related]
18. Hemolytic uremic syndrome with hypocomplementemia, serum C3NeF, and glomerular deposits of C3.
Barré P; Kaplan BS; de Chadarévian JP; Drummond KN
Arch Pathol Lab Med; 1977 Jul; 101(7):357-61. PubMed ID: 577389
[TBL] [Abstract][Full Text] [Related]
19. Incorporation of human complement C8 into the membrane attack complex is mediated by a binding site located within the C8beta MACPF domain.
Brannen CL; Sodetz JM
Mol Immunol; 2007 Feb; 44(5):960-5. PubMed ID: 16624411
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome.
Vaziri-Sani F; Holmberg L; Sjöholm AG; Kristoffersson AC; Manea M; Frémeaux-Bacchi V; Fehrman-Ekholm I; Raafat R; Karpman D
Kidney Int; 2006 Mar; 69(6):981-8. PubMed ID: 16528247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
